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Abstract. In spite of the fact that cholesterol does not pass the blood-brain barrier (BBB), hypercholesterolemia has been linked to
increased Alzheimer’s disease (AD) risk. Hypertension is another risk factor and angiotensin converting enzyme (ACE) activity
is known to be increased in AD. Furthermore, a lower incidence of AD has been reported in patients taking anti-hypertensive
drugs. Here we show that the levels of angiotensinogen (AGT) and ACE are increased in the cerebrospinal fluid (CSF) of patients
with mild cognitive impairment and AD. Moreover, we show ACE activity in the CSF to be positively correlated with both
plasma and CSF levels of 27-hydroxycholesterol (27-OH), an oxysterol known to pass through the BBB and taken up from the
circulation by the brain. In addition, treatment of rat primary neurons, astrocytes, and human neuroblastoma cells with 27-OH
resulted in increased production of AGT. Our results demonstrate that upregulation of renin-angiotensin system (RAS) in AD
brains occurs not only at the enzymatic level (ACE) but also at the substrate level (AGT). The possibility that 27-OH is part of
a mechanism linking hypercholesterolemia with increased brain RAS activity and increased AD risk is discussed.
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INTRODUCTION
Alzheimer’s disease (AD) is the most notable
dementia-associated neurodegenerative disorder. De-
spite age being the most important determinant for the
disease, it is largely considered a multi-factorial disor-
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der and several risk factors are likely to contribute to
the probability of developing AD [1, 2]. An association
between circulating cholesterol levels, cardiovascular
disease, and hypertension with AD risk have been
demonstrated in previous studies [3]. Although sev-
eral epidemiological studies confirm the observation of
increased incidence of AD with hypercholesterolemia
[4] and increased blood pressure [5], the underlying
mechanisms are still unknown.
The Renin-Angiotensin system (RAS), critically
important for the regulation of blood pressure, is
expressed in several tissues. A complete and functional
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RAS is also present in the brain and is independent
from the RAS of renal origin [6]. Angiotensinogen
(AGT), synthesized by glial cells as well as neurons [7],
is converted into the inactive decapeptide angiotensin I
(AngI) by the action of renin. Angiotensin converting
enzyme (ACE), the principal effector of RAS, fur-
ther converts AngI to angiotensin II (AngII) that acts
on angiotensin II type 1 and 2 receptors (AT1R and
AT2R). In addition to the classical functions on salt
and water homeostasis and regulation of blood pres-
sure, the RAS that is present in the central nervous
system (CNS) appears to participate in the regulation
of multiple brain functions including processing of
sensory information, learning, memory, and emotional
responses [8]. Several pathological processes such as
stroke, depression, and emotional stress, as well as AD,
have been suggested to be associated with dysregula-
tion of the brain RAS [9]. Increased ACE activity has
been demonstrated in different brain regions as well
as in CSF of patients with AD [10, 11]. Furthermore,
polymorphisms in the ACE gene are known suscepti-
bility factors for AD [12, 13]. Moreover, AT1R [14]
and AT2R [15] have also been found to be increased in
AD cortex suggesting an augmented brain RAS activ-
ity during the disease process. To further support the
importance of RAS in AD, AT1R blockers and ACE
inhibitors commonly used in the treatment of hyper-
tension have been associated with lower incidence of
clinically diagnosed AD and improved cognitive func-
tion [16].
In view of the fact that the blood-brain barrier
(BBB) prevents the entry of plasma cholesterol to the
brain [17], it is intriguing how high serum choles-
terol levels influence the risk of AD. In animal models,
a diet-induced hypercholesterolemia has been shown
to contribute to the deposition of amyloid- (A)
[18] and tau hyperphosphorylation [19]. However, the
mechanism by which hypercholesterolemia increases
the risk for AD is not fully understood. In a recent
study, we used cDNA microarrays to study the effects
of a cholesterol-enriched high-fat diet (HFD) on gene
expression in mice brain with the aim of identifying
new cellular pathways linking hypercholesterolemia
and neurodegeneration [20]. Some of the defined
cholesterol-regulated genes were linked to AD pathol-
ogy including ACE and Arginine Vasopressin (AVP).
According to this study, cholesterol in the periphery
appears to be of importance for the regulation of the
brain RAS.
The homeostasis of cholesterol is maintained within
the CNS by a slow conversion of brain cholesterol into
the oxysterol 24S-hydroxycholesterol (24S-OH) that is
capable of passing through the BBB [21]. Another side-
chain oxidized oxysterol, 27-hydroxycholesterol (27-
OH), mainly formed outside the brain, is also able to
cross the BBB [22]. The uptake of this steroid from the
periphery by the brain is quantitatively important [23,
24]. Cholesterol homeostasis appears to be disturbed in
AD patients, with decreased 24S-OH and increased 27-
OH levels in the brain [25]. Plasma levels of cholesterol
and 27-OH are closely correlated and it seems likely
that high levels of cholesterol in the circulation result in
increased influx of 27-OH to the brain. Based on this,
we have suggested that 27-OH may be the missing link
between hypercholesterolemia and AD [26].
In the present paper we investigate the effects of
cholesterol and cholesterol metabolites (24S-OH and
27-OH) on the brain RAS. We therefore designed a
combined approach including analysis of CSF and
plasma samples from controls, progressive mild cog-
nitive impairment (MCI), and AD patients, as well as
in vitro experiments using rat primary neurons and
astroglia cell cultures. Overall, our results are con-
sistent with the idea that there is a mechanistic link
between hypercholesterolemia and hypertension con-
tributing to AD pathology and involving the activation
of brain RAS by 27-OH.
MATERIALS AND METHODS
Cerebrospinal ﬂuid (CSF) studies
CSF was collected for diagnostic purposes by lum-
bar puncture in polypropylene tubes, mixed gently to
avoid gradient effects and centrifuged at 2000xg for
10 min. Aliquots were stored at −80◦C until biochem-
ical analysis.
The patients were referred to the Memory Clinic at
Karolinska University Hospital (Huddinge, Sweden).
In this cross-sectional study, we included three groups;
control (n = 25–28), MCI patients (n = 8–10) and AD
patients (n = 20–21). The control group consisted of
individuals with subjective cognitive impairment. MCI
patients were: (i) not demented; (ii) had subjective self
and/or objective informant report of cognitive decline
and impairment on objective cognitive tasks; (iii) had
preserved basic activities of daily living, and min-
imal impairment in complex instrumental functions
[27]. All the MCI patients used in this study devel-
oped AD within a 3-year period. The AD cases were
diagnosed according to The Diagnostic and Statisti-
cal Manual of Mental Disorders-IV (DSM-IV) criteria.
They were evaluated according to a standard com-
prehensive protocol including clinical examination,
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brain imaging (MRI and SPECT), electroencephalog-
raphy (EEG), analyses of blood and CSF (including
Total-Tau, Phospho-Tau and A1-42), and a detailed
neuropsychological evaluation. The study was con-
ducted under the guidelines of the Declaration of
Helsinki and approved by the ethics committee of the
Karolinska Institutet.
Oxysterol levels determination
Plasma and CSF levels of 24S-OH and 27-OH
were assayed by isotope dilution-mass spectrometry
as described previously [28]. One ml of plasma was
required for the oxysterol assay. In order to optimize
the analysis of the CSF, 10 ng of [2H3]-24S-OH and
10 ng of [2H4]-27-OH were added to 500l of CSF
together with 10l of butylhydroxytoluene (5 mg/ml)
and 20l of EDTA (10 mg/ml). Under the conditions
employed, the limit of detection in the assay used for
CSF 24S-OH and 27-OH was about 0.2 ng/ml.
Measurement of ACE concentration in the
cerebrospinal ﬂuid
The concentration of ACE in the CSF was mea-
sured by established enzyme-linked immunosorbent
assay (ELISA) system (R & D systems, Minneapolis,
Minnesota, USA). We first tested samples at different
dilutions (1 : 10, 1 : 5, and 1 : 2) using the calibrator
diluent (RD6-45), to optimize the conditions and war-
ranting the precision of the assay. We determined
that the best dilution was 2-fold (25l CSF samples
+25l diluent per well) since the concentration val-
ues obtained were proximate to the standard curve
midpoint.
Brain tissue preparation
Postmortem brain material was obtained from the
Brain Bank at Karolinska Institutet (Karolinska Uni-
versity Hospital, Huddinge, Sweden) with approval by
the Human Ethics Committee of Karolinska Univer-
sity Hospital. Samples from temporal cortex from 4 AD
brains (two males, 79 and 89 years old; two females 76
and 80 years old) and three aged-matched controls (two
males, 66 and 83 years old; one 83 years old female)
were used for Immunohistochemistry. All brains had a
postmortem delay between 24 and 48 h. The AD cases
had a Mini-Mental State Examination (MMSE) score
between 2 and 15 and met the clinical diagnosis of
probable AD (DSM-IV criteria) as well as definite AD
according to the CERAD neuropathological criteria.
Brain samples were fixed in buffered 4% formaldehyde
and embedded in paraffin.
Immunohistochemistry
Sections (7m thick) were mounted onto Superfrost
plus-glass (Menzel Braunschweig, Germany). Unspe-
cific binding was blocked by 5% normal goat serum
(Sigma-Aldrich, St. Louis, MO, USA) in PBS for
30 min before incubation with the anti-AGT antibody
(Abbiotec, CA, USA) diluted in PBS with 1% BSA
overnight at 4◦C. The sections were rinsed in PBS and
incubated with biotinylated goat IgG for 2 h at room
temperature. Rinsed in PBS between steps, the sections
were incubated with avidin-biotin-peroxidase complex
(Vectastain Elite ABC reagent, Vector Laboratories,
CA, USA), exposed to diaminobenzidine (DAB) and
mounted with mounting medium (DAKO Cytomation,
Denmark). For control staining, the primary antibody
was omitted.
Cell cultures and treatments
Cortical tissue from 18-day-old Sprague-Dawley rat
embryos were homogenized in neurobasal medium
supplemented with of 2% B27 (Invitrogen, Sweden).
Cells from each embryo were seeded separately in
dishes, pre-coated with 0.17 mg/ml poly-D-lysine
MW 300,000 (Sigma-Aldrich, Sweden) in PBS.
Cerebellum from 18-day-old Sprague-Dawley rat
embryos were mechanically dissociated and seeded
in Dulbecco’s modified Eagles medium (DMEM/F12)
containing 10% fetal bovine serum (FBS) for the
preparation of rat primary astrocyte cultures as pre-
viously described [29]. Cells were plated in dishes
with poly-D-lysine (Sigma-Aldrich, Sweden). Cul-
tures were kept at 37ºC in a moist atmosphere (95%
air/5% CO2). Culture media were replaced twice a
week.
Fourteen-day-old cultures were used for all experi-
ments. At this time, astrocytes dominated as identified
by immunocytochemical characterization [29]. Cul-
tures used for the experiments contained on average
300,000 ± 10,000 cells per well. Most cells were flat,
resembling inactivated astrocytes. Ethical consent for
experiments with primary cultures was received from
the regional ethical committee of Karolinska Institutet.
Neuroblastoma SH-SY5Y cells were cultured at
37ºC, 5% CO2, in Eagle’s Minimum essential medium
with Glutamax containing 10% FBS (Sigma-Aldrich,
Sweden). Treatments with 27-OH (Steraloids, New-
port, Rhode Island, USA) were done at 1 or 10M for
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Table 1
Demographic, clinical and biochemical characteristics of control, MCI and AD patients. Values
are represented as mean ± SEM (∗∗p < 0.01, ∗p < 0.05)
Control MCI AD
Demographic
n 25–28 8–10 20–21
Gender (male/female) 9/19 7/3 7/14
Age 57.81 ± 1.27 61.2 ± 2.33 67.3 ± 1.70∗
Education (years) 14.38 ± 0.60 12.33 ± 1.43 10.50 ± 0.82
ApoE4 carrier (%) 33.33 67.60 64.28
MMSE 29 ± 0.21 28.1 ± .0.28 24.05 ± 0.86∗∗
Plasma
Cholesterol (g/L) 2.22 ± 0.06 2.30 ± 0.05 2.25 ± 0.07
24S-OH (g/L) 56.30 ± 1.80 49.73 ± 1.67∗ 48.45 ± 2.64∗
27-OH (g/L) 223.69 ± 10.30 181.5 ± 16.60∗ 174.28 ± 11.34∗∗
HDL (mM/L) 1.57 ± 0.06 1.86 ± 0.07 1.58 ± 0.08
LDL (mM/L) 3.58 ± 0.14 3.63 ± 0.14 3.43 ± 0.15
CSF
Total tau (ng/L) 278.70 ± 27.39 471.4 ± 83.81∗ 626.6 ± 80.96∗∗
P-tau (ng/L) 54 ± 4.73 69.5 ± 14.17 88.7 ± 9.26∗∗
A42 (ng/L) 760.96 ± 40.43 423.37 ± 24.44∗ 536.13 ± 41.16∗∗
ApoE (g/L) 3.73 ± 0.25 3.65 ± 0.39 4.16 ± 0.30
Cholesterol (mg/L) 2.75 ± 0.14 2.81 ± 0.23 3.04 ± 0.15
CSF 24S-OH (g/L) 2.69 ± 0.15 3.25 ± 0.29 3.39 ± 0.40
CSF 27-OH (g/L) 0.37 ± 0.04 0.46 ± 0.10 0.59 ± 0.07∗
ACE (ng/ml) 3.58 ± 0.21 4.41 ± 0.21∗ 4.27 ± 0.27∗
24 h. Subsequent to treatments, cells were collected
and lysed in a lysis buffer (50 mM Tris-HCl, 150 mM
NaCl, 2 mM EDTA, 2 mM EGTA, 1% Triton-X100)
containing protease inhibitor and phosphatase inhibitor
cocktails (Sigma-Aldrich, Sweden).
Immunoblotting
Equal amounts of proteins were separated using 10%
acrylamide gel and later transferred to a nitrocellu-
lose membrane (Schleicher & Schuell, Germany). The
blots were incubated with AGT antibody (Abbiotec,
CA, USA), angiotensin (N-10) antibody (Santa Cruz
Biotechnology, CA, USA) or actin antibody (Sigma
Aldrich, Sweden). The angiotensin (N-10) antibody
recognizes both AngI and AngII, which result from
the consecutive cleavage of AGT by renin and ACE,
respectively. Incubation with primary antibodies were
performed overnight at 1 : 1000 dilution, followed
by incubation with anti-rabbit or anti-mouse IgG
at 1 : 5000 dilution (Amersham Biosciences, Little
Chalfont, England). Immunoreactivity was detected by
the ECL detection system (Amersham Biosciences,
Little Chalfont, England). Some immunoblots were
stripped using Restore™ Western Blot Stripping buffer
(Pierce, Rockford, IL, USA) at room temperature for
15 min. The relative densities of the immunoreactive
bands were calculated from the optical density (OD) of
the selected area using ImageJ 1.37 v software (NIH,
MA, USA).
Statistical analysis
Results are expressed as a mean ± SEM. Normal-
ity was checked by Shapiro-Wilks test before any
further statistical analysis. An analysis of covariance
(ANCOVA) with age and gender as the covariate was
used to compare differences in biochemical measure-
ments between control, MCI and AD patients. Partial
correlations with age, gender, and grouping effect as
confounding variables were used to assess associations
between biochemical and clinical variables of patients.
Results from in vitro experiments were analyzed by
Student’s t test. A value of p < 0.05 was considered
statistically significant in all analyses.
RESULTS
Correlation of cholesterol and 27-OH with members
of the Renin-Angiotensin System in Alzheimer’s
disease patients
The demographic, clinical and biochemical charac-
teristics of the subjects enrolled in our study are shown
in Table 1. AD patients were observed to be signifi-
cantly older than the controls (F(2,58) = 8.33, p < 0.05).
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Fig. 1. Correlation between ACE and 27-OH levels in MCI and AD. A) ACE concentrations in CSF from control, MCI, and AD cases. Vertical
box histogram shows the quantification of ACE (ng/ml) obtained by established enzyme-linked immunosorbent assay (ELISA) system (∗p < 0.05
vs. Control). B) Correlations between levels of ACE and plasma 27-OH (for AD-MCI group: r = 0.34, p < 0.05; left panel) and CSF 27-OH (for
AD-MCI group: r = 0.49, p < 0.01; right panel). C: Control, AD: Alzheimer’s disease.
Due to this age difference, we examined the results
following the correction for age and gender. Clini-
cally, it was observed that AD patients presented with
a significantly lower MMSE score (F(2,58) = 14.79,
p < 0.01) than the controls. However, in regards to
the characteristics of AD, the CSF total tau (T-tau)
(F(2,56) = 7.89, p < 0.01) and CSF phosphorylated-tau
(p-tau) (F(2,51) = 4.00, p < 0.01) levels were higher than
the controls in AD patients. Additionally, the levels of
CSF A1-42 (F(2,53) = 8.82, p < 0.01) were observed to
be lower in both AD and MCI cases.
In agreement with previous studies [28], CSF lev-
els of 27-OH in AD patients were found to be higher
(F(2,44) = 3.31, p < 0.05) while 24S-OH showed an aug-
mented trend (F(2,51) = 1.93, p = 0.16) with respect
to the control group. The plasma levels of 27-OH
(F(2,53) = 7.41, p < 0.01) and 24S-OH (F(2,53) = 4.34,
p < 0.05) were found to be significantly lower in AD
and MCI individuals when compared to controls as
expected [28]. Cholesterol levels in both plasma and
CSF displayed no significant changes between con-
trols, AD or MCI patients.
As previously reported [11], ACE levels measured
by ELISA in the CSF were significantly higher in
MCI and AD patients (F(2,54) = 3.15, p < 0.05) than
controls (Table 1 and Fig. 1A). Interestingly, an asso-
ciation between 27-OH and CSF-ACE was clearly
observed. Both the plasma and CSF levels of 27-
OH were positively correlated with CSF ACE in AD
(r = 0.34, p < 0.05, n = 20 for plasma-AD; r = 0.49,
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Table 2
Correlations between levels of total cholesterol, 27-OH and 24S-OH
(in plasma and CSF), and CSF biochemical markers for AD as well
as cognitive score. Table shows correlations in the AD-MCI group.
Age, gender, and grouping effect were used as confounding variables
r p-value
CSF 24S-OH vs CSF A42 −0.145 0.16
CSF 24S-OH vs CSF T-tau 0.468 <0.01∗∗
CSF 24S-OH vs CSF p-tau 0.535 <0.01∗∗
CSF 24S-OH vs MMSE 0.103 0.24
Plasma 24S-OH vs CSF A42 −0.07 0.33
Plasma 24S-OH vs CSF T-tau −0.16 0.14
Plasma 24S-OH vs CSF p-tau −0.09 0.28
Plasma 24S-OH vs MMSE −0.04 0.38
CSF 27-OH vs CSF A42 −0.06 0.35
CSF 27-OH vs CSF T-tau 0.22 0.05∗
CSF 27-OH vs CSF p-tau 0.15 0.17
CSF 27-OH vs MMSE −0.07 0.33
Plasma 27-OH vs CSF A42 0.30 <0.05∗
Plasma 27-OH vs CSF T-tau −0.09 0.27
Plasma 27-OH vs CSF p-tau 0.05 0.37
Plasma 27-OH vs MMSE −0.02 0.45
CSF Chol vs CSF A42 0.25 0.06
CSF Chol vs CSF T-tau 0.26 <0.05∗
CSF Chol vs CSF p-tau 0.31 <0.05∗
CSF Chol vs MMSE 0.08 0.31
Plasma Chol vs CSF A42 0.11 0.25
Plasma Chol vs CSF T-tau 0.19 0.11
Plasma Chol vs CSF p-tau 0.17 0.15
Plasma Chol vs MMSE 0.11 0.24
CSF 24S-OH/27-OH vs CSF A42 −0.13 0.20
CSF 24S-OH/27-OH vs CSF T-tau 0.03 0.44
CSF 24S-OH/27-OH vs CSF p-tau 0.09 0.28
CSF 24S-OH/27-OH vs MMSE 0.15 0.16
Plasma 24S-OH/27-OH vs CSF A42 −0.32 <0.05∗
Plasma 24S-OH/27-OH vs CSF T-tau −0.11 0.23
Plasma 24S-OH/27-OH vs CSF p-tau −0.2 0.1
Plasma 24S-OH/27-OH vs MMSE −0.06 0.34
r = correlation coefficient after correcting for grouping effect and
age. ∗p < 0.05; ∗∗p < 0.01.
p < 0.01, n = 20 for CSF-AD) but not with the con-
trols after correcting for the confounding variables, i.e.,
age and gender (Fig. 1B). However, no correlation was
observed between plasma/CSF levels of 24S-OH or
cholesterol and the ACE levels in CSF.
Next we compared the levels of oxysterols and total
cholesterol with pathological and clinical features of
AD (Table 2). Here, we found after correcting for
grouping effect and age, a correlation between the CSF
levels of 24S-OH and CSF levels of both T-tau and p-
tau (r = 0.47, p < 0.01; r = 0.54, p < 0.01 respectively).
Moreover, the CSF levels of 27-OH and CSF T-tau
(r = 0.22, p = 0.05) in addition to the plasma levels of
27-OH and CSF A1-42 levels (r = 0.30, p < 0.05) were
also seen to correlate. Cholesterol present in the CSF
correlated with both T-tau and p-tau present in the CSF
(r = 0.26, p < 0.05; r = 0.31, p < 0.05 respectively). As
for the level of A1-42 in the CSF, a correlation was
observed with the ratio of 24S-OH/27-OH present in
the plasma of AD patients.
Increased levels of angiotensinogen (AGT) in MCI
and AD patients
Levels of AGT and AngI/II were analyzed in CSF
samples from controls, MCI and AD individuals by
immunoblotting. As seen in Fig. 2A, AGT was signif-
icantly increased in the CSF of MCI and AD patients
compared to controls. A trend towards increased
levels of AngI/II was observed in AD patients (con-
trol = 100 ± 20.46; AD = 152.89 ± 27.48), although
these changes were not statistically significant.
Furthermore, immunohistochemical analysis re-
vealed that, in control brains, AGT immunoreactiv-
ity was localized mostly in the cytosolic compartment
of neurons (Fig. 2B). In AD brains, AGT was gen-
erally reduced in healthy looking neurons (determined
according to Oppenheimer’s criteria, including the cen-
tral position of the nucleus and the presence of a single
large conspicuous nucleolus) (“a” in Fig. 2B). How-
ever, an intense AGT immunoreactivity was found in
some neurons with certain morphological phenotype
resembling ghost neurons (“b” in Fig. 2B). Addition-
ally, compared to controls, AD brains revealed an
increased AGT immunoreactivity in glia-like profiles
(“c” in Fig. 2B).
27-OH enhances angiotensinogen production
in cultured cells
Since astroglia are thought to be the most impor-
tant source of AGT in the brain [30], we tested the
impact of 27-OH on AGT production in rat primary
astrocytes. Non-significant increase was found in the
cellular levels of AGT protein in astrocytes exposed to
27-OH (data not shown). However, as shown in Fig. 3A
(left panel), treatment of astrocytes with 27-OH (1M)
resulted in a significant increase in secreted levels of
AGT protein (150% of control, p < 0.05). On the other
hand, a higher concentration of 27-OH (10M) caused
a slight but non-significant increase on AGT produc-
tion (Fig. 3A, right panel).
In rat primary neuronal cultures, both concentrations
of 27-OH (1M and 10M) induced a significant
increase on cellular levels of AGT (Fig. 3B). As seen
in Fig. 3C this effect was also present in SH-SY5Y
neuroblastoma cells.
DISCUSSION
In accordance to previous studies, our results
showed that ACE levels in the CSF are increased in
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and increased in glial-like profiles (“c”). In AD samples, an intense AGT immunoreactivity was found in some neurons with morphological
phenotype resembling ghost neurons (“b”). Scale bars = 50m. C: Control, AD: Alzheimer’s disease.
patients with AD and MCI after the correction for age
and gender (Fig. 1A) [11]. However, our study demon-
strates for the first time that another component of the
brain RAS; AGT, is also increased in the CSF of these
patients (Fig. 2A). This indicates that upregulation of
brain RAS in AD does not only occur at the level of
the enzymatic proteolysis (ACE activity) but also at
the substrate level (AGT). Since AGT levels in CSF
were also increased in progressive MCI (patients that
will develop AD in 3 years time), our results suggest
that RAS upregulation occurs early and not only in the
final stages of the disease.
We analyzed the possibility that 27-OH mediates the
upregulation of brain RAS under in vivo conditions in
humans. We found a significant correlation between
the levels of 27-OH and ACE in the CSF from patients
(MCI and AD) (Fig. 1B). However, a correlation did
not exist between blood cholesterol and CSF-ACE.
Similarly, levels of 24S-OH and ACE in the CSF were
not correlated. It is well documented that the levels
of 27-OH are increased in the CSF of patients with
neurodegenerative diseases [31]; this was also con-
firmed in the present study (Table 1). The reason for the
increase is not completely understood but it has been
suggested that one factor of importance could be a rel-
ative deficiency of the metabolizing enzyme CYP7B1
[22]. Since this enzyme is located in neurons, neu-
ronal damage may result in the impaired capacity to
metabolize 27-OH.
It has been previously suggested that 27-OH could
play an active role in AD pathogenesis. Supporting
this contention, we found a correlation between the
levels of this oxysterol and features of AD such as
CSF levels of A1-42, T-tau, and p-tau. We have pre-
viously shown that 27-OH reduces the expression of
the activity-regulated cytoskeleton-associated protein
(Arc), a factor important for memory consolidation
[20]. 27-OH has also been shown to antagonize the pre-
ventive effect of 24S-OH in the generation of A [22]
and to increase A production in neuronal prepara-
tions from adult rabbit brain [32]. Based on the results
obtained in this study, it is suggested that increased
27-OH influx to the brain may activate brain RAS.
In an attempt to clarify as to whether the above find-
ings really refer to a potential role for the metabolism
of cholesterol in the modulation of the RAS system
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Fig. 3. 27-OH enhances AGT production in astrocytes and neurons. A) Media (100l) from astrocytes treated with 27-OH (1M and
10M; 24 h) were immunoblotted with anti-AGT antibody. Ponceau staining was used as a loading control. At 1M, 27-OH was able to
induce a significant increase on AGT secretion in astrocytes (∗p < 0.05 vs. Control, left panel). B) Lysates from rat primary neurons treated
with 27-OH (1M and 10M; 24 h) were immunoblotted with anti-AGT antibody. 27-OH induced a strong increase on AGT production at
both concentrations (∗p < 0.05 vs. Control). C) Human neuroblastoma SH-SY5Y cells treated with 27-OH (1M and 10M; 24 h) and lysates
immunoblotted with anti-AGT antibody. Data were normalized as ratios to total protein levels in the respective lysates (A) and to actin (B and C),
and presented as mean ± SEM.
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and not just to a single parallelism in the development
of AD pathology, we next performed in vitro exper-
imental studies by treating cells with 27-OH. In the
brain, most AGT is produced by astrocytes. We found
that 27-OH induced a significant increase in AGT
production in rat astrocyte cultures, as evidenced by
increased AGT levels present in conditioned media. An
increase in AGT production was found also in treated
neurons (rat primary cultures and human neuroblas-
toma cells), suggesting a general non-cell specific
mechanism. However, in AD brains, we showed by
immunohistochemistry an increased AGT immunore-
activity in glial cells and a decrease in healthy looking
neurons. Therefore, a more complex disruption in AGT
production/cleavage in the late stages of AD could
be assumed. Nevertheless, the results of in vitro and
in vivo experiments presented here are consistent with
the assertion that an increased flux of 27-OH into the
brain is associated with an upregulation of the brain
RAS in the course of AD.
Several studies have shown that cholesterol-en-
riched diet (HFD) induces cognitive deficits in mice
[33, 34]. ApoE-knockout mice fed with HFD revealed
increased levels of 27-OH but unchanged levels of
24S-OH in the brain [35]. We recently showed that
HFD induced changes in the expression of several
genes in mice brains including ACE [20]. On the other
hand, recent studies reported that transgenic mice
expressing human renin and AGT genes (hRN/hAGT-
Tg) have impaired cognition, increased oxidative
stress in the brain, and ischemic brain damage medi-
ated by overstimulation of AT1R [36, 37]. It is evident
that brain RAS is important for a variety of neuronal
functions as well as for the regulation of cerebral
blood flow [38]. The effects of AngII mainly mediated
by AT1R include vasoconstriction and vasopressin
release in the brain [39] but it is also implicated in
mechanisms that may be significant in AD such as
transforming growth factor-beta signaling [40], BBB
maintenance [41], and cell survival [42]. Accumulat-
ing data support the association of hypertension with
declining cognitive function and dementia [43] while
management of blood pressure with antihypertensive
drugs is partially effective for the prevention of cogni-
tive decline in older adults [44], including those with
AD [45]. Furthermore, animal studies have shown
that ACE inhibitors enhance cognitive performance
[46] and improve learning and retention of memory
[47]. These experiments have led to the hypothesis
that ACE inhibitors facilitate cognitive processes by
reduction of available AngII, which regulates cerebral
blood flow by stimulating cerebral vasoconstriction
via AT1R. Moreover, it has been reported that AT1R
blockers attenuate ischemic brain damage [48]. On the
other hand, RAS upregulation inducing the overstimu-
lation of AT1R leads to cognitive deficits and ischemic
damage in mice [36, 37]; as well as hypertension,
vascular brain damage and insulin resistance in
humans [49], known risk factors for AD [50].
In summary, the present results are consistent with
the ideas that 1) the metabolism of peripheral choles-
terol is of importance for the modulation of RAS in
the brain, and 2) that 27-OH may be a link between
the neurodegenerative effects caused by high blood
cholesterol levels and hypertension.
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